Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study evaluates the combination of the autophagy inhibitor hydroxychloroquine (HCQ), the MEK inhibitor tunlametinib, and the anti-PD-1 antibody pucotenlimab in patients with locally advanced or metastatic melanoma. The primary objectives are to assess the objective response rate (ORR) and progression-free survival (PFS). Secondary objectives include evaluating adverse events (type, severity, and incidence), duration of response (DOR), disease control rate (DCR), and overall survival (OS), as well as exploring the molecular mechanisms by which autophagy modulation enhances immunogenicity in mutant melanoma. Further exploratory analyses will examine the mechanisms by which autophagy inhibition enhances tumor sensitivity to PD-1 blockade, thereby establishing experimental and theoretical grounds for refining future clinical approaches.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat, niezależnie od płci
- •Czerniak w zaawansowanym stadium (III lub IV), który nie da się operować lub ma przerzuty, potwierdzone badaniem histologicznym
- •Mutacja genu NRAS potwierdzona badaniem genetycznym
- •Wcześniejsze leczenie przeciwnowotworowe jest dozwolone, ale skutki uboczne muszą być łagodne
- •Ogólny stan zdrowia pozwalający na leczenie (skala ECOG 0-2)
- •Oczekiwana długość życia co najmniej 12 miesięcy
- •Prawidłowe funkcje wątroby, nerek i szpiku kostnego (określone wartościami w krwi)
- •Co najmniej jeden widoczny guz do zmierzenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Sun Yat-sen University
Guangzhou, China
Trial contact
Rong cheng Zhang MD, PhD
Dandan Li MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.